(5-Bromo-2-chlorophenyl)[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methanone is a synthetic organic compound featuring a benzophenone core substituted with bromo and chloro groups on one phenyl ring and a tetrahydrofuran-3-yloxy group on the other. It is a key chiral intermediate in the synthesis of Palbociclib (PD-0332991), a highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). This compound is specifically used in the final stages of Palbociclib's synthetic route. Palbociclib is an FDA-approved oral medication used for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. The precise stereochemistry and substitution pattern of this intermediate are critical for the biological activity of the final drug molecule. As a specialized pharmaceutical intermediate, it is not a general-purpose synthetic building block. Its production and handling are primarily within the context of active pharmaceutical ingredient (API) manufacturing for targeted cancer therapies.